Hubei Biocause Pharmaceutical announced that in the first half of 2024, China Best Life Insurance Co., Ltd. achieved an original insurance premium income of 24.608 billion yuan. Among them, the renewal premium was 14.552 billion yuan, an increase of 47% year-on-year, and the proportion of scale premium increased from 28% last year to 56%. The new business value rate effectively increased, achieving a new business value of 1.986 billion yuan, an increase of 575% compared to the same period last year. Overall, China Best Life's operation is stable, and the business structure continues to be optimized.
天茂集团：国华人寿上半年新业务价值大幅度增长
Hubei Biocause Pharmaceutical: China Best Life Insurance's new business value in the first half of the year has significantly increased.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated